What to Know About Peptides the FDA Is Considering for Use
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA advisory committee voted last week in favor of widening access to six of seven peptides that had been previously banned over safety concerns.
- FDA staff scientists had warned the panel there was a lack of safety and efficacy data on the compounds, yet the committee voted to expand access to six of them.
- The seven peptides are being evaluated by the FDA for specific medical uses, including treating ulcerative colitis, insomnia, and osteoporosis.
- Despite being prohibited, the peptides are widely purchased by consumers from longevity clinics, alternative health providers, biohacking influencers, and TikTok, often produced in unregulated labs in China and sold as "research grade" compounds.
- BPC-157, also called Body Protection Compound or bepecin, is identified in the article as one of the most popular "gray market" peptides among consumers.
- If cleared, the compounds could be marketed and used for many purposes beyond the FDA's specific evaluated indications, potentially compounding the existing off-label gray-market use.
- Cross-coverage consensus: The only other visible headline — NYT Health's "F.D.A. Panel's Vote on Peptides Raises Concerns About a Prescribing Boom" — frames the vote as fueling a prescribing boom, while the source text emphasizes a parallel concern: FDA staff scientists themselves flagged missing safety data on the very compounds the panel voted to expand.
Why it matters: If the FDA follows its advisory panel, compounding pharmacies could legally produce six peptides that the agency's own scientists said lacked adequate safety and efficacy data. A gray market already exists — fed by unregulated Chinese labs and TikTok-driven demand — so FDA clearance would legitimize and widen a supply chain the agency itself acknowledges it cannot currently vouch for.
